Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | DRD3 | P35462 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13179111 | 0.81 | RAB9A (0.55) | RAB9ADRD2DRD3MEN1NPC1 | |
| SCHEMBL8393737 | 0.81 | RAB9A (0.64) | RAB9ADRD2DRD3MEN1NPC1 | |
| SCHEMBL14734297 | 0.79 | DRD2 (0.63) | RAB9ADRD2DRD3MEN1NPC1 | |
| SCHEMBL10498437 | 0.79 | RAB9A (0.49) | RAB9ADRD2DRD3MEN1NPC1 | |
| SCHEMBL31662444 | 0.78 | RAB9A (0.47) | RAB9ADRD2DRD3MEN1NPC1 | |
| SCHEMBL14734298 | 0.78 | DRD2 (0.61) | RAB9ADRD2DRD3HDAC1CYP1A1 | |
| SCHEMBL18937416 | 0.78 | RAB9A (0.69) | RAB9ADRD2DRD3MEN1NPC1 | |
| SCHEMBL2963194 | 0.78 | DRD2 (0.61) | RAB9ADRD2DRD3MEN1NPC1 | |
| SCHEMBL10498805 | 0.76 | SIRT6 (0.46) | RAB9ADRD2DRD3MEN1KMT2A | |
| SCHEMBL14708663 | 0.76 | CYP1A1 (0.47) | RAB9ADRD2DRD3HDAC1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | RAB9A 4678/4885DRD2 3669/4885DRD3 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.